GlyCardial Diagnostics has developed an accurate and proprietary biomarker for the early detection of cardiac ischemia using a simple blood test.
17M
Cardiovascular disease is the leading cause of death globally causing 31% of total deaths
25%
Of the general population will experience chest pain during their lifetime
2-20%
Of chest pain patients are wrongly discharged depending on the geographical area
3k-12k€
Cost per patient admitted with chest pain suggestive of an ischemic event
Inaccurate diagnosis may lead to increased death rates, other cardiovascular events and high costs
Available biomarkers only allow us to see the tip of the iceberg, so a lab-representation of ischemia is missing.
Early detection of ischemia is essential to administer therapy and prevent progressive myocardial damage.
iSCOR could support most of the strategies for the improvement of chest pain management
01
Reduce in-hospital delay for identifying and treating patients with an ischemic event
02
Prevent innappropriate release of patients with an ischemic event
03
Reduce unnecessary hospitalization rate for non-ischemic patients
04
Reduce medical costs in the assessment of chest pain patients
